Oncolytics Biotech (ONCY) Change in Cash (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Change in Cash data on file, last reported at -$5.9 million in Q4 2025.

• On a quarterly basis, Change in Cash fell 82.28% year-over-year to -$5.9 million in Q4 2025; TTM through Dec 2025 was -$8.2 million, a 45.4% increase from a year earlier, with the FY2025 full-year figure at -$5.9 million, up 61.63% from the prior year.
• Change in Cash for Q4 2025 stood at -$5.9 million, down from -$1.8 million in the prior quarter.
• Over the last five years, Change in Cash for ONCY reached as high as $16.4 million in Q3 2023 and fell as low as -$15.0 million in Q4 2022.
• Historically, Change in Cash has averaged -$1.1 million across 5 years, with a median of -$2.8 million in 2021.
• Across the five-year window, Change in Cash plunged 654.63% in 2022 and soared 793.21% in 2023, its largest moves.
• Year by year, Change in Cash stood at -$5.1 million in 2021, then plunged by 193.39% to -$15.0 million in 2022, then soared by 78.58% to -$3.2 million in 2023, then dropped by 0.3% to -$3.2 million in 2024, then tumbled by 82.28% to -$5.9 million in 2025.
• Per Business Quant data, the three most recent Change in Cash figures were -$5.9 million in Q4 2025, -$1.8 million in Q3 2025, and -$70727.8 in Q2 2025.